Member Info for The_Paladin

“Primarily by people who don’t think the companies worth anything.”

Let us adhere to the facts at our disposal.

1. The value of our shareholdings at the current time is < 6p per share.

2. The market values Synairgen according to its perceived cash reserve. We will know the latter’s exact value during the next compulsory company update.

3. 23 months ago there was a catastrophic collapse in the company’s market valuation owing to the failure of a Phase III trial.

4. In the absence of any incoming revenue since then, the share price has decreased over 23 months to its current value.

5. There have been false dawns in the last 23 months, the most recent being the expectation that a clinical trial would be conducted during the Winter of 2022-2023. That failed to materialise. No explanation was offered to investors as to why it didn’t happen ?

6. We have currently been led to believe that company-led clinical trials are scheduled sometime during H1 2024. Investors’ last update on the latter was exactly 4 months ago.

It is not surprising that investors are voicing doubt about the capabilities of the CEO and BOD. Shareholders confidence is primarily based on the value of their shareholding and their belief in its future growth potential. If and when there is a significant announcement that will reverse the continued decline in the value of our respective shareholdings, our gloomy outlook may well change at that time.

Finally, I see no hidden shorters or traders on this board who are attempting to reduce the company’s value. I do however believe that there are a number of disappointed LTIs who regularly or occasionally contribute here. In any event, any contribution to a niche share forum is unlikely to have any effect on the share price for the reason stated above.

A weird day altogether. I have just received a LinkedIn message from IB providing a link to the “latest” newsletter in case I missed it. The link took me to the newsletter issued in September 2023.

I have little idea what is going on here? When we were recently informed that the CLNs were cleared, it was reasonable to expect a period of stability, and even growth as successive company RNSs were issued. Today’s share price action was a bolt out of the blue. I have no idea what brought it about bearing in mind that company information has led us to believe that there will be positive incoming news in the near future?

Thank you Doc.Daneeka. My best wishes to you, and to all Synairgen long term investors. Hopefully the company will update us on their plans before too long!

I was checking on CV-19 variant JN.1 earlier today as I am taking a long multi-stage journey this Friday. The most recent articles from the Medical Centres of US Universities tally with the information in that New Scientist article. Despite this, I will be strictly following standard procedures on flights, trains, and even taxis. With the rapid growth and spread of JV.1 it is better to try to stay safe than have regrets later on.

https://www.yalemedicine.org/news/jn1-coronavirus-variant-covid

I have also read up generally on the prevalence of respiratory infections. Sadly (from an altruistic perspective), I concur with all contributors to this forum that there will be more than sufficient severely infected patients available whenever Synairgen is able to conduct its proposed trials. I specifically focused on SARS-CoV-2, influenza, and RSV and assumed that patients suffering from these viruses would be invited to participate in the Synairgen trials.

Thank you KaneonAim. I failed to spot the last IB newsletter, although the company has highlighted many important developments on X in recent months. I am happy that TB and KS have cleared their outstanding CLNs, and look forward to a positive market response to further incoming news.

The shareholder synergy on this forum is first rate. My thanks to everyone for your contributions and positivity.

An interesting point for research and discussion. The references that I looked at were fairly low level. I discovered that it is not an exact science. Pros and cons were listed, and exact criteria need to be established in order to guide clinicians.

* Aerosol delivery by nebulizers and pressurized metered-dose inhalers (pMDIs) attached through an adapter or spacer into a ventilation circuit during noninvasive mechanical ventilation (NIV) and high flow nasal cannula (HFNC) add great benefits in the management of obstructive lung disease patients.

* The inhaled medication, given during NIV and HFNC, offers better and quicker clinical effects than with unassisted breathing.

* Unfortunately, there is no specific recommendation or guidelines to guide therapists/clinicians in their decisions while delivering aerosols to ventilated patients which puts the patients at risk of receiving either a sub-therapeutic or toxic dose of their inhaled medications.

* This increases the urgency for the development of recommendations/guidelines by a trusted board/society for aerosol delivery to such critically ill patients.

These points were c/p from a basic article published in 2020, and may well be out of date by now. I recall thinking at the time of the Sprinter trial whether Synairgen might have selected severely ill patients on ventilators ? This was because of previous statements about the need for patients in this category to effectively demonstrate the efficacy of SNG001. On reflection, a naive thought on my part, but it kind of made sense at the time

Gunto. Regarding your final sentence, the answer is both. Work that one out if you are able?

Gunto

You are the board specialist on making defamatory comments about others who disagree with your point of view. Your views about Synairgen, or about myself and other posters, are of no importance to me. The only relevant issue to know that the company is doing its utmost in getting my investment back on track.

It is your business if you are satisfied with a statement made over 3 months ago, effectively postponing any future trial by up to nine months. I doubt whether many serious investors share your point of view?

Much has been written by contributors about this aspect of my investment this week. Most investors are only too aware as to our drug’s value following a successful Phase III trial. Should all go well, it could yet result in a moonshot opportunity for us all.

However, I would be reassured if the company could update investors as to their current progress towards getting the proposed trials underway. No serious investor should be satisfied by the statement last September that these small company trials, all being well, would go ahead sometime during the following nine months.

Synairgen have had nearly 23 months to prepare for these trials. I have monitored the situation closely during that time. IMHO they have meandered before finally arriving at a strategy broadly presented at the AGM last May.

I agree with all investors, who are of the opinion that we need some reassurance whether the strategy will be actuated or not during H1 2024? A simple statement to investors either way as soon as possible would suffice. Surely, they must know by now whether these trials will take place before the end of June?

I have done just that MrCosts.

I trusted the company to get the business done two years ago. This time around, a brief message to investors informing us whether they are on track to get the trials underway during H1 would be appreciated. This is what I said. Let us see whether there is a reply?

I am concerned that there has been no update regarding the company led P2 trials for well over 3 months. Are they scheduled to take place during the Winter when there is a greater opportunity to recruit patients with severe symptoms? Investors’ contributions to the LSE SNG chat forum in recent days will illustrate investors’ concerns about the lack of information concerning progress with these trials. I do not expect a reply, but a general update to investors via your X/ LinkedIn spaces would be appreciated.

With thanks,

Dr. ……………………

40m shares altogether in four sells within the same minute. I concur with all who maintain that the share price is being controlled by a large entity. This is not the work of retail investors.

Mr. Zamboni’s web of complexities makes it virtually impossible for investors to figure out what is going on? One thing for sure, it is has involved share price manipulation for the two years or so that I have been invested.

I am probably not the only investor to realise that I should have sold at a loss @ 0.14p last year. Should the share price eventual recover to those levels I will finally leave this merry go round.

No problem as regards the trials dunk. It is just that Tommy is unable to accept the fact that his data will only assume any relevance to my Synairgen investment when the trials commence.

Tommy/Fruits I am unimpressed by your deflection techniques. Deliberate misinterpretation of another contributor’s comment to score points on a niche share forum is not the best use of your obvious skills.

My final attempt.

Tommy.

Your data will be important and relevant, when the forthcoming Synairgen P2 trials are being conducted. Until we reach that point, it is of no value to me as an investor.

Last Winter’s data , at a time when I was expecting a trial to commence is of little value to Synairgen today. This will be the case with the current data should the trials not go ahead.

IMHO, the trials will happen during Q2 2024. That is pure speculation on my part. My opinion is of no value until they actually start.

You are deflecting there Tommy. When, and ONLY when, we have information concerning the Phase II trials, will the current data assume any significance.

It has been 117 days since the last relevant company trial announcement. As stated earlier, I am not expecting an update until Q2 2024. Until that happens, all your comments, although peripherally interesting, are not currently relevant to my Synairgen investment.

“They’re out in force today trying to down play NHS data.”

Tommy.

When will you begin to understand that it is not about the infections/hospitalisations data, but all to do with an announcement from Synairgen, hopefully during H1 2024, as to when they will be in a position to make full use of it?

Meanwhile, do calm down. We are all investors on this board, despite what you may think? If not, why are we bothering to waste time commenting on a niche forum about a company with a massively depleted share price, and an uncommunicative executive team?

“I always find the way you express your views on this share as quite telling.”

What exactly do my expressed views tell you Tommy? I could well put forward a similar sentiment about what your consistent narrative suggests to me. As in the case of your opinion about my contributions, it would be purely personal and speculative.

Once again Tommy, you are quick to judge and respond without first reading what a contributor has written. The number of infections and hospitalisations will ONLY BE RELEVANT AS REGARDS MY SYNAIRGEN INVESTMENT, once I have definite information about the forthcoming trials.

Until then, as previously stated, these statistics may well have significance for individuals who are most likely to succumb to infection. However, should the next six months pass without a trial announcement from Synairgen, they are totally irrelevant as regards my investment.

The statistics on numbers of infections and hospitalisations are important to those of us who are likely to succumb to infection for whatever reason, or have relatives and friends in the same category.

From the point of view of my Synairgen investment, they are irrelevant for the time being. At the end of last Winter, with its own set of infection and hospitalisation statistics, I was disappointed that there was no trial announcement, as had been hinted in previous information shared by the company.

This time around there is more information about the forthcoming Phase II company trials, although the dates for their commencement currently lie somewhere within a 6-month window.

I am grateful to all contributors who offer peripheral information, and personal opinions concerning the nature and possible starting dates of these trials. My best guess, given my 41 month involvement as an investor, is that they will start early on in Q2, 2024. However, like the opinion of every other investor, until there is a definite announcement from the company, my prediction is pure speculation.

A successful outcome to the P2 trials should result in a significant share price uplift. The company would then be poised for a BP buyout offer, possibly doubling the share price. 100p is possible this year given a serendipitous combination of circumstances. Wasn't Simon Shaw alluding to something like this at the last AGM?

My thanks to all forum contributors whose research and insights have added extensively to my knowledge over the last week or so.

If the company’s detailed strategy announcement, presumably during mid to late H1, is close to that perceived by our contributors then we should be well and truly back on track.

We will know when the company has turned a corner when the share price embarks on a steady and sustained rise. Until then, we can but continue to wait until the Synairgen Board has detailed information to communicate with investors. My best guess for the timing of a significant RNS is sometime during Q2 at the earliest. Meanwhile, the company will continued to be valued according to the remainder of the shareholder investment from late 2020 that remains on deposit.